截至月份: 2025年9月30日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 大健康國際集團控股有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02211 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 500,000,000 | USD | | 0.1 | USD | | 50,000,000 | 本月底法定/註冊 ...

Core Viewpoint - The company reported a significant decline in revenue and an increase in losses for the fiscal year ending June 30, 2025, primarily due to the impact of new healthcare policies in China [1] Financial Performance - The company recorded revenue of RMB 710 million, a year-on-year decrease of 34.7% [1] - The loss attributable to shareholders was RMB 26 million, compared to a profit of RMB 400,000 in 2024 [1] - Earnings per share were RMB -0.3246, a decline from an adjusted profit of RMB 0.0062 per share in 2024 [1] Market and Operational Challenges - Revenue decline was attributed to the new healthcare policies in China and a decrease in the number of active customers within the national distribution network [1] - The company is actively participating in alliance activities to enhance its industry influence and brand product development [1] Strategic Initiatives - The company is focusing on national strategic initiatives such as "Healthy China," "Beautiful China," "Belt and Road," "Guangdong-Hong Kong-Macao Greater Bay Area," and "Hainan Free Trade Port" to guide its business transformation and upgrade [1] - The company aims to leverage industry experience and focus on technological innovation to explore further business transformation directions [1]

Core Points - The company reported a revenue of approximately 711.5 million, representing a year-on-year decrease of 34.7% [1] - Gross profit was approximately 113.4 million, down 37% year-on-year [1] - The company recorded a loss attributable to owners of 26.06 million, marking a shift from profit to loss compared to the previous year [1] - Earnings per share were reported at a loss of 32.46 cents [1] Revenue Analysis - The decline in revenue is primarily attributed to the impact of new healthcare insurance policies in China [1] - Additionally, there was a decrease in the number of active customers within the national distribution network [1]

Group 1 - The company reported a revenue of approximately 711.5 million, representing a year-on-year decrease of 34.7% [1] - Gross profit was approximately 113.4 million, down 37% compared to the previous year [1] - The company experienced a loss attributable to owners of 26.06 million, marking a shift from profit to loss year-on-year [1] - Earnings per share were reported at a loss of 32.46 cents [1] Group 2 - The decline in revenue is primarily attributed to the impact of new healthcare insurance policies in China [1] - There was a decrease in the number of active customers within the national distribution network [1]

Financial Performance - Total revenue for the year ended June 30, 2025, was RMB 711.5 million, a decrease of 34.7% compared to RMB 1,089.0 million in 2024[3] - Gross profit for the same period was RMB 113.4 million, down 37.0% from RMB 179.9 million in the previous year[3] - The company reported an operating loss of RMB 25.5 million, a decline of RMB 25.6 million from a profit of RMB 0.1 million in 2024[3] - Net loss for the year was RMB 25.7 million, compared to a profit of RMB 0.6 million in 2024, representing a decrease of RMB 26.3 million[3] - Basic loss per share was RMB 32.46, down from earnings of RMB 0.62 per share in the previous year, a decline of RMB 33.08[5] - The gross profit margin decreased to 15.9%, down 0.6 percentage points from 16.5% in 2024[3] - For the fiscal year ending June 30, 2025, total revenue was RMB 774,379,000, a decrease from RMB 1,214,697,000 in the previous year, representing a decline of approximately 36.3%[24] - The company reported a net loss of RMB 25,674,000 for the fiscal year ending June 30, 2025, compared to a net profit of RMB 580,000 in the previous year[24][25] - The loss attributable to the owners of the company was RMB 26.0 million, compared to a profit of RMB 0.4 million in the previous year[50] Assets and Liabilities - Total assets decreased to RMB 447.6 million from RMB 692.9 million in 2024, a decline of 35.4%[6] - Current assets fell to RMB 171.0 million, down from RMB 295.7 million in the previous year, a decrease of 42.1%[6] - Total liabilities decreased to RMB 130.0 million from RMB 340.0 million in 2024, a reduction of 61.8%[7] - The total assets as of June 30, 2025, amounted to RMB 447,603,000, a decrease from RMB 692,877,000 in the previous year, indicating a reduction of approximately 35.3%[24][25] - The total liabilities as of June 30, 2025, were RMB 130,029,000, down from RMB 339,992,000, reflecting a decrease of about 61.8%[24][25] Cash Flow and Financing - The company recorded a net cash outflow from operating activities of RMB 59.8 million for the year[9] - The net cash flow used in operating activities was RMB 59.8 million, a decrease from RMB 101.7 million in the previous year, primarily due to reduced revenue leading to lower inventory purchases[61] - The company has sufficient resources to continue operations for at least the next 12 months, with no significant uncertainties affecting its ability to continue as a going concern[10] - As of June 30, 2025, the company has available but undrawn bank financing of RMB 50,000,000 and loans from former joint ventures amounting to RMB 40,000,000[11] - The company continues to negotiate external financing options, including obtaining further loan financing and refinancing existing loans[11] Operational Changes - The company has closed several loss-making retail stores to minimize cash outflows, which is expected to improve operating profit margins and cash flow[11] - The company has implemented cost control measures to enhance operational efficiency and improve future cash flows[11] - The company has reduced its brand product offerings by 315, maintaining a total of 223 brand products by the end of the year[44] - The company operates a total of 120 chain stores, with a projected increase to 203 stores by 2024[41] - The active customer base in the national distribution network fell to approximately 1,027 from 1,515 in the previous year, with a notable decline in both retail and distributor customers[54] Revenue Breakdown - Revenue from external customers for the year ended June 30, 2025, was RMB 711,509,000, a decrease from RMB 1,089,037,000 for the year ended June 30, 2024[21] - The breakdown of revenue for the year ended June 30, 2025, includes RMB 140,374,000 from prescription drugs and RMB 502,432,000 from over-the-counter drugs[21] - The revenue from external customers for the distribution segment was RMB 513,626,000, while the retail segment generated RMB 197,883,000, contributing to a total external revenue of RMB 711,509,000[24] - The retail business revenue for the year was RMB 197.9 million, a year-on-year decrease of 40.4%[41] - The distribution business revenue was RMB 513.6 million, down 32.1% year-on-year[42] Employee and Operational Metrics - Employee benefit expenses decreased to RMB 68,195,000 in 2025 from RMB 113,440,000 in 2024, a reduction of about 40%[27] - As of June 30, 2025, the group had 842 full-time employees, a decrease from 1,286 in 2024, with total employee benefits expenditure amounting to RMB 68.2 million, down from RMB 113.4 million in 2024[67] Corporate Governance - The company is committed to maintaining high standards of corporate governance and has adopted the corporate governance code as per listing rules, ensuring compliance with applicable provisions[75] - The audit committee consists of three independent non-executive directors, responsible for overseeing the group's financial data and reporting processes[76] - The group's auditor confirmed that the figures in the annual performance announcement align with the audited consolidated financial statements[77] - The company has adopted a code of conduct for securities trading that meets or exceeds the standards set forth in the listing rules[78] Strategic Initiatives - The company plans to focus on the health sector, particularly the pharmaceutical industry, while optimizing its retail network and exploring structural transformation and digital upgrades[69] - The "Professional+" strategy aims to enhance service professionalism and operational quality, leveraging pharmacists and business school advantages to improve pharmaceutical service levels[69] - The "Platform+" strategy will expand value-added services in stores to meet growing consumer health demands, including aging and chronic disease management[70] - The "Internet+" strategy will strengthen the connection between physical stores and online platforms, utilizing new technologies and marketing ecosystems to enhance competitiveness[70] Market Trends - The Chinese government is increasingly focusing on the development of traditional Chinese medicine, with policies aimed at promoting high-quality development in the healthcare sector[36] - The market size of China's health industry is projected to reach RMB 29.1 trillion by 2030, driven by aging population and rising health awareness[36] - Technological innovations such as AI, big data, and IoT are being widely applied in healthcare, enhancing diagnostic efficiency and service quality[37] - The company is expected to accelerate the construction of elderly care service systems and improve service quality in 2024[37] - The company is focusing on community and home-based elderly care services to meet diverse aging needs[37]

Core Viewpoint - The company, Great Health International (02211.HK), anticipates a net loss of no less than RMB 25.7 million for the fiscal year ending June 30, 2025, following a net profit of approximately RMB 600,000 for the fiscal year ending June 30, 2024 [1] Financial Performance - The transition from net profit to net loss is primarily attributed to the recognition of gains from the sale of subsidiaries in the fiscal year ending June 30, 2024 [1]

据董事所深知，由净溢利转为净亏损乃主要归因于截至2024年6月30日止年度，出售附属公司的收益已 于损益中确认。 智通财经APP讯，大健康国际(02211)发布公告，预期集团将于本年度(截至2025年6月30日止年度)取得 净亏损不少于人民币2570万元，而截至2024年6月30日止年度则取得约人民币60万元的净溢利。 ...

大健康国际(02211)发布公告，预期集团将于本年度(截至2025年6月30日止年度)取得净亏损不少于人民 币2570万元，而截至2024年6月30日止年度则取得约人民币60万元的净溢利。 据董事所深知，由净溢利转为净亏损乃主要归因于截至2024年6月30日止年度，出售附属公司的收益已 于损益中确认。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 2211 UNIVERSAL HEALTH INTERNATIONAL GROUP HOLDING LIMITED 盈利預警 本公告乃由大健康國際集團控股有限公司（「本公司」，連同其附屬公司，統稱「本集團」） 根據聯交所證券上市規則（「上市規則」）第13.09條以及香港法例第571章證券及期貨條例第 XIVA部項下內幕消息條文（定義見上市規則）而作出。 本公司董事會（分別為「董事」及「董事會」）謹此知會本公司股東（「股東」）及潛在投資者， 基於對本集團截至2025年6月30日止年度（「本年度」）的未經審核綜合管理賬目及董事會目 前可得資料作出的初步評估，預期本集團將於本年度錄得淨虧損不少於人民幣25.7百萬 元，而截至2024年6月30日止年度則錄得約人民幣0.6百萬元的淨溢利。據董事所深知，由 淨溢利轉為淨虧損乃主要歸因於截至二零二四年六月三十日止年度，出售附屬公司之收 益已於損益中確認。 承董事會命 ...

Core Viewpoint - ST Hongda announced significant changes in its leadership, with Huang Jun resigning as chairman and Xu Guoxing stepping in as the new chairman, while Huang Jun will take over as the general manager [1] Group 1: Leadership Changes - Huang Jun resigned from the position of chairman due to work changes but will continue as a director [1] - Xu Guoxing was elected as the new chairman of the seventh board of directors, effective immediately upon the board's approval [1] - Xu Guoxing also resigned from his role as general manager due to work changes, remaining as a director [1] - Huang Jun has been appointed as the new general manager, effective immediately upon the board's approval [1]